Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Update: 2025-12-09
Description
Host: Ryan Quigley
Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies.
Comments
In Channel



